>>Description of the research protocol "GO-BEYOND"

GO-BEYOND. A prospective observational study to assess the real world effectiveness of golimumab in patients with active rheumatoid arthritis 5RA), psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) and failure of an initial tumor necrosis facto
Status : Ongoing and recruiting

Additional details

Indication (or studied pathology) : PA, SA et Arthrite psoriasique
Brugmann identifier : GO-BEYOND
EudraCT identifier : B670201733034


Involved department : Rheumatology
Principal investigator : Bentin
Sponsor : MDS
Contact : Clinical Research Unit

>This protocol was approved by the UZ Gent ethics committee.